Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR and PD-1 knock out engineered T-cells
- Development stage
- Phase 1
- Lead developer
- Caribou Biosciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR and PD-1 knock out engineered T-cells are autologous T cells that have been genetically modified to express a Chimeric Antigen Receptor (CAR) targeting the CD19 protein and to have the Programmed Death-1 (PD-1) gene knocked out. This investigational medicinal product is designed to treat relapsed or refractory CD19-positive malignant B-cell derived leukemia and lymphoma, including Acute Lymphoblastic Leukemia and Burkitt Lymphoma, by enhancing the T-cells' ability to recognize and eliminate cancer cells while overcoming immune checkpoints.
- Other names
- CD19 Chimeric Antigen Receptor (CAR) and PD-1 knock out engineered T-cells
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CD19 CAR and PD-1 knock out engineered T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR and PD-1 knock out engineered T-cells.